HEARTCARE-B (06609) has announced that the Group anticipates generating revenue between approximately RMB 4 billion and RMB 4.1 billion for the year ending December 31, 2025 (the reporting period). This represents an increase of at least 43.9% compared to the revenue of RMB 2.78 billion for the year ended December 31, 2024. The Group also expects to achieve a pre-tax profit of approximately RMB 80 million for the reporting period, marking a substantial improvement from the pre-tax net loss of RMB 12 million recorded for the year ended December 31, 2024. This revenue growth is primarily driven by several key factors: the launch of new products and technologies for ischemic stroke, coupled with an increased market share for its ischemic stroke product portfolio; the scaled commercialisation of intracranial stents and rising sales volumes of other hemorrhagic stroke products; and the continued sales growth of interventional access products. Furthermore, the Group has effectively reduced its expense ratio through stringent cost control measures targeting both cost of sales and administrative expenses.